---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-001727"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T14:36:33.220926+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADMA Q4 revs ~$49-50M (+89% YoY), FY22 revs ~$153-154M (+90%); guides FY23 revs $210M+, first positive EBITDA in H2 2023

## Summary
- Q4 2022 preliminary revs ~$49-50M, up ~89% YoY; FY22 revs ~$153-154M, up ~90% over FY21.
- FY2023 revenue guidance of $210M or more, representing ~40% YoY growth.
- First-time positive EBITDA expected in second half of 2023.
- Plans to open tenth plasma collection center and obtain FDA licensure for three additional centers in 2023.
- Long-term financial targets reiterated; current trends tracking at upper bound of expectations.

## SEC filing metadata
- accession: 0001140361-23-001727
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/brhc10046612_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-001727
- JSON: https://secwatch.observer/filing/0001140361-23-001727.json
- Plain text: https://secwatch.observer/filing/0001140361-23-001727.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. updated its 2023 guidance (initiated).
  - Period: 2023
  - Guidance: initiated
  - Result: guidance update
  source text: ADMA currently anticipates full year 2023 total revenues of $210 million or more.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm
- Earnings Releases
  ADMA BIOLOGICS, INC. reported fourth quarter and full year 2022 results: revenue preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million. Guidance reaffirmed.
  - Period: fourth quarter and full year 2022
  - Revenue: preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: ADMA Biologics, Inc. (the “Company”) issued a press release announcing its preliminary unaudited fourth quarter and full year 2022 revenues and providing 2023 financial guidance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.